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Summary. Background: Glanzmann thrombasthenia (GT) is a
congenital bleeding disorder caused by either a lack or
dysfunction of the platelet integrin aIIbb3. Objectives: To
determine the molecular basis of GT in patients from southern
India. Patients: Fifteen unrelated patients whose diagnosis was
consistent with GT were evaluated. Results: Platelet surface
expression of aIIbb3 was < 10%, 10%–50%, and > 50% of
controls in five, nine, and one patient(s), respectively.
Immunoblotting of the platelet lysates showed no aIIb in 14
patients, and no b3 in 10 patients, although severely reduced in
four patients. Platelet fibrinogen was undetectable in 13
patients, and severely reduced in one patient. One patient
showed normal surface aIIbb3 expression, and normal aIIb, b3
and fibrinogen levels in the lysate. Ten novel candidate disease-
causing mutations were identified in 11 patients. The missense
mutations included Gly128Ser, Ser287Leu, Gly357Ser,
Arg520Trp, Leu799Arg in aIIb, and Cys575Gly in b3. We have
already shown that Gly128Ser, Ser287Leu, and Gly357Ser
mutations variably affect aIIbb3 surface expression. The
Cys575Gly mutation may disrupt the disulphide link with
Cys586 to cause theGTphenotype.Themolecular pathologyof
the other missense mutations is not clear. Two nonsense
mutations, Trp-16Stop and Glu715Stop in aIIb, and a 7-bp
deletion (330-336TCCCCAG) in b3 are predicted to result in
truncated proteins. An IVS15()1)G fi A mutation in aIIb
induced a cryptic splice site as confirmed by reverse transcrip-
tion-polymerase chain reaction (RT-PCR) analysis. Thirteen
polymorphisms were also identified (five in aIIb and eight in b3),
among which five were novel. Conclusions:While identifying a
significant number of novel mutations causing GT, this study
confirms the genetic heterogeneity of the disorder in southern
India.
Keywords: aIIbb3, Glanzmann thrombasthenia, mutations,
polymorphisms.
Introduction
Glanzmann thrombasthenia (GT) is a rare, autosomal
recessive bleeding disorder characterized by a life-long
mucocutaneous bleeding tendency, absent or severely
reduced platelet aggregation in response to the physiological
agonists adenosine 5¢-diphosphate (ADP), epinephrine, and
collagen, and a relatively normal initial phase of aggregation
in response to ristocetin [1–3]. The disease is caused either
by a lack or dysfunction of the platelet integrin aIIbb3
(glycoprotein IIb/IIIa), which serves as a receptor for
fibrinogen, von Willebrand factor, and perhaps other
adhesive glycoproteins [4]. More than 100 candidate dis-
ease-causing mutations in either aIIb and/or b3 genes have
been identified in patients with GT worldwide, including
deletions, insertions, inversions, single nucleotide substitu-
tions that lead to missense or nonsense mutations, and
splicing defects [5–8]. Certain mutations predominate in a
given population, such as Iraqi Jews and French Gypsies
[9,10]. Although rare in the general population (1:200 000
among a population of 60 million in Iran) [11], it occurs in
high frequency in certain ethnic populations with an
increased incidence of consanguinity such as in south
Indians, Iranians, Iraqi Jews, Palestinian and Jordanian
Arabs, and French Gypsies [9–12].
In this paper, clinical, hematological, biochemical and
molecular genetic data on 15 unrelated GT patients from
southern India are presented, bringing to light 10 novel
mutations and five novel polymorphisms in the aIIb or b3
genes.
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Materials and methods
Sample processing
The study was approved by the ethics committee at the
Christian Medical College, Vellore, India. Platelet-rich
plasma (PRP) was prepared from blood that was anticoag-
ulated with citrate or ethylenediaminetetraacetic acid
(EDTA). Peripheral blood was collected after obtaining
informed consent from patients diagnosed as having GT
based on clinical and hematological evaluation. A portion of
the citrated PRP was used for flow cytometry analysis. The
EDTA-anticoagulated PRP and the remaining citrated PRP
were washed separately in Tris–saline–EDTA buffer (TSE,
pH 7.4). The citrated platelet pellet was resuspended in 70%
ethanol and stored at )80 C. The EDTA pellet was
resuspended in the wash buffer to a final platelet count of
2 · 109 cells mL)1, lysed with an equal volume of lysis
solution [6 mM N-ethyl maleimide in 3.3% sodium dode-
cylsulfate (SDS)], heated immediately to 100 C for 3 min
and then cooled and frozen at )80 C. Genomic DNA was
extracted from the buffy coat using a standard phenol–
chloroform method.
Analysis of platelet surface expression of aIIbb3
Mouse monoclonal antibodies (mAbs) 10E5 (anti-aIIbb3,
CD41/61), 7E3 (anti-aIIbb3 + anti-aVb3, CD41/61 and
CD51/61, respectively) and 6D1 (anti-GPIb, CD42b) were
added to the citrated PRP, followed by incubation with
FITC-conjugated goat-antimouse antibody (Cappel; ICN
Pharmaceuticals, Columbus, OH, USA). Appropriate IgG1
and IgG2a isotype control antibodies were also analyzed
[gifts from Dr Kenneth Bradstock (Westmead Hospital,
Sydney, Australia)]. Surface expression was analyzed in a
flow cytometer (Bryte-HS, Bio-Rad, Hercules, CA, USA)
using WinBryte software.
Total platelet content of aIIbb3
Lysates of washed platelets solubilized in SDS [13] were
subjected to SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) using precast gels (PhastGel Homogenous 7.5;
Pharmacia Biotech, Uppsala, Sweden). Equivalent amounts
of protein were added to each lane. Samples for aIIb were
tested reduced to display both pro-aIIb and the heavy chain
of mature (cleaved) aIIb, and samples for b3 were tested non-
reduced. The separated proteins were blotted onto polyviny-
lidene fluoride (PVDF) membranes and incubated separately
with murine mAbs specific for aIIb (CD41, SZ22) and b3
(CD61, SZ21) (Immunotech, Marseille, Cedex, France).
Secondary labeling was done with a gold-conjugated goat
antimouse IgG (Auroprobe One GAM; Amersham Interna-
tional PLC, Buckinghamshire, UK), followed by enhance-
ment of the gold stain using a silver reagent (IntenSE BL;
Amersham).
Mutation analysis of aIIb and b3 genes
A total of 38 PCR reactions were performed on genomic DNA
using intragenic primers as previously described [14,15] or
additional primers and conditions that can be obtained by
contacting one of us (A.S.). Briefly, PCR amplification was
carried out using100 ng genomic DNA, 0.2–0.4 lM primers,
125 lM dNTPs, 1.5–2.0 mM MgCl2, 1 U of DNA polymerase
(DyNAzyme II; Finnzymes, Espoo, Finland), and reaction
buffer (50 mM KCl, 10 mM Tris–HCl, pH 8.3) in a total
volume of 25 lL. Single-strand conformation polymorphism
(SSCP) analysis was performed by either an automated
(PhastGel System; Pharmacia Biotech) or manual method
(Protean II Cell; Bio-Rad). The gels were silver-stained as per
the manufacturer’s protocol (Pharmacia Biotech).
Amplicons that showed mobility shifts by SSCP analysis
were purified from 2.5% agarose gel (GeneClean II Kit; Bio
101, Carlsbad, CA, USA) and their DNA sequence was
determined (Big Dye terminator kit; Applied Biosystems,
Foster City, CA, USA) using an automated sequencer (ABI
310 Genetic Analyzer; Applied Biosystems).
mRNA isolation was performed from platelets stored in
70% ethanol at )80 C according to the manufacturer’s
instructions (QuickPrep Micro mRNA purification kit; Amer-
sham Biosciences, Piscataway, NJ, USA). The cDNA was
synthesized using a random hexamer according to the manu-
facturer’s protocol (Superscript First-strand Synthesis System;
Invitrogen Corporation, Carlsbad, CA,USA). PCR for b-actin
was done to check the efficiency of platelet mRNA isolation.
For the aIIb IVS15()1) G fi A mutation, PCR was done
using the primers, 5¢ 1252: GGCCAAGTGCTGGTGTTC
and CTCCATGCAGCACGACAG: 1858 3¢, spanning aIIb
exons 13–18. For the b3 TCCCCAG 330–336 deletion in exon
3, primers spanning b3 exons 1–6 were used, namely 5¢: 28
CTCTGGGTGACTGTGCTGG and CCGTCATTAGGC-
TGGACAAT: 890 3¢.
Restriction fragment length polymorphism (RFLP) analysis
RFLP was performed for the previously unpublished poly-
morphisms, using NlaIII, BanII, BsaJI, BslI, and HaeIII
restriction enzymes (MBI Fermentas GmbH, St Leon-Rot,
Germany).
Results
Patient characteristics
The clinical, hematological, immunophenotypic, surface mem-
brane protein, and molecular genetic data on the 15 patients
evaluated at our center are summarized in Tables 1 and 2. All
the patients were from southern India, predominantly from the
states of Tamil Nadu and Andhra Pradesh. The age of onset of
symptoms ranged from 0 to 7 years (mean 2 years), but the age
at definitive diagnosis ranged from 4 to 41 years (median
14 years). Eleven patients were born to known consanguineous
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parents, and six of them had a family history of bleeding. The
predominant clinical manifestations included skin andmucosal
bleeding both affecting nearly all patients. Five patients
(33.3%) had received red cell or platelet transfusions on more
than five occasions and 11 of them had been transfused at least
once. Though there were no platelet aggregation responses to
physiological agonists in any of the patients, some patients had
residual, albeit reduced, clot retraction (3/15, 20%), and some
had poor initial phase responses to ristocetin (3/15, 20%).
Platelet surface expression of GPIb and aIIbb3 receptors
The mean platelet surface expression level of GPIb was 79.4%
of controls (range 44.8%–96.4%) as shown by the binding of
anti-GPIb antibody, 6D1 (CD42b). Platelet aIIbb3 expression
was < 10% of controls in five patients, 10–50% in nine
patients, and 95% in one patient.
aIIb, b3 and fibrinogen in the platelet lysates
Fibrinogen was undetectable in the platelet lysates in 13
patients, and severely reduced in one, as revealed by Coomassie
blue-stained SDS-PAGE gels. Immunoblot analysis of the
platelet lysates revealed no traces of aIIb in 14 patients. b3 was
undetectable in the platelet lysates in 10 patients, and severely
reduced in four. However, in one patient, aIIb, b3 and
fibrinogen were present at normal levels.
Mutations in the aIIb and b3 genes
Probable disease-causing homozygous mutations were found
in 11 out of 15 patients (73%), nine in aIIb and two in b3, of
which 10 were novel (eight in aIIb and two in b3). Of the 10
candidate disease-causing mutations identified, six were mis-
sense, two were nonsense, one was a small deletion (7 bp) and
one was a splice site mutation (Tables 1 and 2).
Missense mutations (n ¼ 6) Six novel missense mutations
were identified in aIIb exons 4, 11, 12, 17, and 25, namely
Gly128Ser (GGT > AGT), Ser287Leu (TCG > TTG),
Gly357Ser (GGC > AGC), Arg520Trp (CGG > TGG),
and Leu799Arg (CTC > CGC). Arg520Trp was identified in
patients 6 and 7, and Cys575Gly was found in b3 exon 11,
TGC > GGC in patient 11.
Nonsense mutations (n ¼ 2) Twonovelnonsensemutations
were identified in aIIb exons 1 and 22 in patients 1 and 8,
respectively. The mutation in exon 1 occurred within the signal
peptide sequence (Trp-16Stop; TGG > TGA) and hence it is
predicted to completely prevent synthesis of aIIb protein. The
other mutation, Glu715Stop (GAG > TAG) identified in
patient 8 is predicted to result in a truncated aIIb protein.
Splice mutation (n ¼ 1) A novel point mutation at the
splice acceptor site of aIIb intron 15, IVS15()1)G fi A [3¢
splice site, AG fi AA] was seen in patient 5, and thisTa
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mutation was confirmed by digestion with AluI restriction
enzyme. RT-PCR analysis using primers encompassing aIIb
exons 13–18 revealed two cDNA products of equal amounts,
but grossly diminished when compared with the amount of
cDNA in the normal control. One of these matched the control
amplicon size of 607 bp while the other amplicon was about
750 bp in length (Fig. 1).
Deletion (n ¼ 1) A novel 7-bp deletion, namely
TCCCCAG 330–336, in b3 exon 3 was identified in patient
10. This mutation is predicted to result in a shift in the reading
frame at Ser110 and eventually lead to premature termination
at the new codon position 141. RT-PCR analysis using primers
encompassing b3 exons 1–6, revealed a cDNA product moving
very closely with the control amplicon of size 863 bp (Fig. 2),
sequencing of which confirmed the 7-bp deletion.
Polymorphisms in the aIIb and b3 genes
Apart from the 10 candidate disease-causing mutations, 13
polymorphisms were also identified, five in aIIb and eight in b3,
of which five have not been previously reported, namely aIIb
IVS16(+11)T fi C, and IVS26(+22)G fi T, and b3 5¢-
UTR-114G fi C, 5¢-UTR-35insG, and 5¢-
UTR()24)G fi C. One private polymorphism, aIIb
IVS16(+11)T > C, was not observed in any of the 53
unrelated healthy controls tested. The polymorphism aIIb
IVS26(+22)G > T was present in all those tested, indicating
that this could be a very common polymorphism in the south
Indian population, or an error in the published sequence
(GenBank accession no. J02764). Three aIIb polymorphisms
previously reported to be in linkage disequilibrium [16] were
also found in six patients (homozygous), IVS21()7)C fi G,
2622T fi G in exon 26, and 3063C fi T in exon 30. The
2622T fi G (843Ile fi Ser) substitution is part of the
human platelet alloantigen HPA-3 system. The HPA-1 system,
b3 176T fi C (33Leu fi Pro) substitution in exon 3 was
identified in four patients, three of whom were heterozygous.
Three patients were heterozygous for two previously reported
polymorphisms in b3 exon 10, 1533G fi A (485Glu fi
Glu) and 1545A fi G (489Arg fi Arg) [15]. One patient
was heterozygous for another polymorphism in b3 exon 10,
1641C fi T (495Cys fi Cys), whereas another b3 IVS10
(+23)C fi G polymorphism was identified in the hetero-
zygous form in two patients.
Discussion
GT has been reported among Indian patients by several groups
[17–22], including a series of 42 patients from southern India
which was described from our center in 1981 [12]. GT is the
fourth most common inherited bleeding disorder in southern
India, after hemophilia A and B and von Willebrand disease
(S. C. Nair, S. Baidya, M. Chandy, A. Srivastava, unpublished
observation). We have recently reported 23 mutations, of
which 20 were novel, among 40 patients with GT, mostly from
southern India [23] seen at our center between 1996 and 1998
during a collaborative study involving our center and those in
Tel-Hashomer, Israel and New York, USA. The current paper
describes the results of evaluation of 15 unrelated patients with
GTwho presented subsequently at our center in 1999 and 2000.
Ten more novel mutations were found among them. Fourteen
novel mutations have also been described in the b3 gene among
patients from western India [24–26].
There is significant heterogeneity in clinical presentations
among the patients included in the current study, with the age
of onset of symptoms varying from birth to 7 years, though
most were symptomatic by their second year. Diagnosis was
delayed by almost a decade in most cases, reflecting the lack of
awareness and facilities available for detecting this rare
disorder. It is also significant that the median age of the
patients was about 14 years and no patient was older than
41 years. It is likely therefore that GT affects survival in our
population where the current life expectancy is about 65 years.
Parental consanguinity (73% vs. 63%), family history of
bleeding (40% vs. 38%) and absence of clot retraction (80% vs.
88%) were found to be consistent with our previous study [23].
603 bp
872 bp
607 bp
C P N M
Fig. 1. Reverse transcription-polymerase chain reaction (RT-PCR)
analysis for the aIIb IVS15()1)G fi A splice site mutation showing
diminished amounts of the two splice variants (607 bp and 750 bp). C,
control cDNA; P, patient cDNA; N, PCR negative; M, /X 174 HaeIII
marker.
863 bp
(control)
872 bp
M C P N
Fig. 2. Reverse transcription-polymerase chain reaction (RT-PCR) ana-
lysis for the b3 330–336 TCCCCAG deletion showing a transcript moving
very closely with the normal control transcript of 863 bp, consistent with
the 7-bp deletion. C, control cDNA; P, patient cDNA; N, PCR negative;
M, /X 174 HaeIII marker.
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The clinical presentation was similar to previous reports with
respect to consanguinity, sites of bleeding, and transfusion
frequencies [1]. Gingival bleeding alone was the most frequent
symptom, being reported in 93.3% of our patients. This
symptom has been particularly difficult to manage in one
family with two affected siblings with almost continuous
bleeding requiring multiple platelet transfusions. The cause for
this remains unclear. Menorrhagia was present in all female
patients above the age of puberty.
Different types of mutations were identified among 11
patients in this study, such as missense, nonsense, deletion, and
splice sitemutations, thus conforming to the genetic diversity of
this disorder in southern India [23]. Recently, we described in
detail, the aIIb mutations, namely G128S, S287L, and G357S,
that are located in the highly conserved cage motif within the
b-propeller domain [27]. Including the above, 11 candidate
mutations have been reported within the b-propeller domain of
aIIb affecting receptor biogenesis and/or function [28–34].
The 575Cys fi Gly mutation is located in the region
encoding the fourth cysteine-rich repeat of b3 (I-EGF-4
domain). There are a total of 56 cysteine residues in b3 that
are involved in intra-chain disulphide bond formations.
Mutation of Cys575 is predicted to disrupt the disulphide
bond with Cys586, and hence could affect b3 folding [24].
Evidence points to the development of a GT phenotype if the
short-range disulphide bonds in the protease-sensitive region of
b3 are interfered with, resulting in a misfolded protein [35]. A
mutation affecting the same Cys575 residue namely, Cy-
s575Arg was previously reported in a homozygous form in
three affected siblings (two of them dizygotic twins) and in a
heterozygous form in three other patients in Italy [7].
The exact mechanism by which the other aIIb missense
mutations identified in this study (Arg520Trp and Leu799Arg)
cause GT has not been determined. The two aIIb nonsense
mutations which were also identified in this study, namely Trp-
16Stop and Glu715Stop are predicted to lead to premature
termination of translation.
The point mutation at the splice acceptor site (AG fi AA)
of intron 15 of aIIb resulted in diminished expression of an
alternatively spliced mRNA transcript, in addition to a
transcript resulting from normal splicing. However, no corres-
ponding protein products were detectable in the platelet lysate,
suggesting that the mutant aIIb mRNA was unstable.
The 7-bp deletion within exon 3 of b3, 330–336 TCCCCAG
is predicted to produce an out-of-frame deletion. RT-PCR
analysis revealed a product of about the size of the normal
control cDNA product, consistent with normal splicing,
sequencing of which confirmed the 7-bp deletion. This deletion
was followed by premature termination of translation at the
new codon position 141 of the mature b3 protein.
In conclusion, these data confirm the genetic diversity of
mutations and polymorphisms in aIIb and b3 genes in patients
with GT in southern India and provides insights into the
structure/function relationships in these genes. As we could not
identify any clear genotype–phenotype correlations and
because the range of bleeding symptoms was quite broad, it
is clear that other genetic and/or environmental factors, still to
be defined, affect the clinical expression of the disorder.
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